

HIV Quasispecies and Resampling

Human immunodeficiency virus (HIV) behaves as an evolving quasispecies in infected individuals. When the populations of genetic variants that make up this quasispecies are characterized, it is common practice to obtain a number of nucleotide sequences by amplifying a region of the viral genome from a small amount of infected tissue [typically 1 microgram (μg) of DNA] by using the polymerase chain reaction (PCR), cloning the amplified products, and selecting a number of clones for sequencing (1). However, if the number of target molecules in the original sample is low, it is unlikely that all the sequences will have been derived from different input templates, and hence estimates of genetic diversity will often be below the true value (2). The controversy [reviewed by Barton F. Haynes *et al.* (Articles, 19 Jan., p. 324)] over whether slow or fast progressors to AIDS achieve higher levels of diversity may be rooted in this phenomenon.

Suppose N target molecules are subjected to PCR so that each is amplified to K molecules. Subsequently, the PCR products are cloned with equivalent efficiency,

and r clones are randomly selected for DNA sequencing. K is very large in a typical PCR relative to r ; hence, the probability distribution representing the frequency of selecting one particular clone follows a binomial function. The average number of distinct clones among r sampled clones is given by

$$N \left[1 - \left(1 - \frac{1}{N} \right)^r \right] \quad (1)$$

The probability of resampling at least one original template is given

$$1 - \frac{\prod_{i=1}^r (N - i + 1)}{N^r} \quad (2)$$

For a given number of clones selected, the higher the input number of target molecules, the higher the average number of unique clones chosen and the lower the probability of resampling. The average number of unique templates that the selected clones represent can also be estimated by formula 1 if the input copy number is known.

Analysis of HIV quasispecies from a commonly sampled source, such as uncultured peripheral blood cells (PBMCs) that typically contain 1 to 100 copies of provi-

ral templates per microgram of DNA (3), can result in a high probability of resampling, especially for cases in which the copy number is low, for example, in slow or nonprogressors (4). For example, if 10 clones are to be sequenced, 25 input templates would give 88% probability of resampling at least one of the original templates. The dilemma of resampling is also evident when other techniques, such as heteroduplex mobility assays (HMAs) and heteroduplex tracking assays (HTAs) (5), are applied to HIV and other biological samples with low copy numbers of target molecules.

To avoid the resampling problem, each clone to be sequenced could be obtained from an independent PCR, which could be an expensive and laborious approach. Alternatively, proper estimation of quasispecies diversity will require quantitation of target templates performed by endpoint dilution (3) or other methods, and consideration of the issue of resampling.

Shan-Lu Liu

Allen G. Rodrigo

Raj Shankarappa

Gerald H. Learn

Department of Microbiology,
University of Washington,
Seattle, WA 98195-7740, USA

HisTrap kit: saving an hour couldn't be simpler

Would you like to save one hour in histidine-tagged protein purification?
To load, purify and elute in 15 minutes? Now it's possible—time after time.

The HisTrap™ Kit presents you with a solution so simple it works with a syringe. Inside the kit is all you'll need for up to ten affinity purification runs: pre-packed cartridges, ready-made stock solutions, a protocol that's easy to follow, and, of course, a syringe.

You'll get high purity recombinant proteins as the kit lets you use the well-known binding of poly(histidine) sequences to immobilized nickel. What's more, it saves you the effort of weighing out buffer salts.

Molecular biologists have been purifying recombinant proteins with Pharmacia Biotech media from the very beginning. Call us at 1 (800) 526 3593 from the USA, +81 (0)3 3492 6949 from Japan or +46 (0)18 16 50 11 from Europe and the rest of the world (or meet us on the Internet at <http://www.biotech.pharmacia.se>). Ask about the kit that saves an hour.

A column from
the HisTrap™ Kit,
magnified 280%.



"Purity, simplicity and time savings: a product that gives you all these, lets you take a break from the lab for a bagel, coffee and...hmm, maybe a haircut?" Kyungsun Suh, Ph.D., at the Rockefeller University, New York, NY

 **Pharmacia
Biotech**
Uppsala, Sweden. (And the rest of the world)

& Isotopically Labelled Compounds

Isotec Inc. pioneered the commercial production of enriched stable isotopes and today, is unsurpassed in custom synthesis capabilities. Currently, we separate and enrich over 30 stable isotopes including those of carbon, deuterium, nitrogen, oxygen and the noble gases. We inventory thousands of isotopically labelled compounds to ensure rapid delivery.

We provide the finest products at competitive prices to researchers in agriculture, biology, chemistry, drug testing, environmental, geology, health, nutrition and physics. Our goal is to support *your* research.

Call for information on products,
custom synthesis, or a FREE catalog:

1-800-448-9760

ISOTEC INC.
A Matheson: USA Company

3858 Benner Road • Miamisburg, OH 45342 U.S.A.
513-859-1808 • Fax 859-4878 • isosales@isotec.com

Circle No. 10 on Readers' Service Card

Li Hsu
Ori Davidov
Lue Ping Zhao

Quantitative Genetic Epidemiology,
Fred Hutchinson Cancer Research Center,
Seattle, WA 98104, USA

James I. Mullins
Departments of Microbiology and Medicine,
University of Washington

References

1. J. M. Coffin, *Science* **267**, 483 (1995).
2. S. Wain-Hobson, *Curr. Top. Microbiol. Immunol.* **176**, 181 (1992).
3. P. Simmonds *et al.*, *J. Virol.* **64**, 864 (1990).
4. Y. Cao, L. Qin, L. Zhang, J. Saifrit, D. D. Ho, *N. Engl. J. Med.* **332**, 201 (1995).
5. E. L. Delwart *et al.*, *Science* **262**, 1257 (1993).

Response: Liu *et al.* point out the inherent difficulties in determining quasispecies diversity, particularly under circumstances where the sample size of target molecules is low. We agree that this might in fact contribute to the discrepancies in the literature regarding the levels of viral diversity in HIV-infected slow versus fast progressors.

As pointed out by Liu *et al.*, the sample size may play a critical role in evaluation of HIV quasispecies diversity. It is conceivable in reports of long-term nonprogressors that

viral diversity was underestimated. Such technical constraints should be kept in mind when results are interpreted concerning patient populations with extremely low viral burdens.

Barton F. Haynes
Department of Medicine,
Duke University Medical Center,
Durham, NC 27710, USA
Giuseppe Pantaleo
Anthony S. Fauci
National Institute of Allergy
and Infectious Diseases,
National Institutes of Health,
Bethesda, MD 20892, USA

Gene Therapy Chronology

Eliot Marshall states in his response to Robert J. Levine (Letters, 24 May, p. 1085) that I “told Levine in June 1995 that [I] did not foresee any possibility of a human trial,” although this is clearly contradicted by Levine’s statement “that the [*New York Times*] story was premature and exaggerated . . . but that as soon as [During] could foresee any possibility of extending [his] work to involve human subjects, [he] would contact [me] promptly.”

MATHEMATICA

EXPERIMENTAL DATA ANALYST

Fitting, visualization, and error analysis with the power of Mathematica

Experimental Data Analyst meets the specific needs of anyone working with experimental data. Essential for researchers and students at all levels, *Experimental Data Analyst* helps you get the most out of your data with its extensive data fitting, error analysis, and visualization capabilities. Here's some of what you can do using *Experimental Data Analyst*:

- import and export ASCII or binary format data
- fit data to linear or arbitrary models
- easily handle errors in both coordinates of the data
- obtain estimated errors in fit parameters and examine graphical information about the fit including residuals
- create impressive two- and three-dimensional graphics including histograms and box plots
- combine text, calculations, and graphics in a single document
- use real experimental data sets from a variety of different fields
- access comprehensive on-line help and free technical support
- and much more...

<http://www.wolfram.com/es>

1-800-441-6284 • info@wolfram.com

**WOLFRAM
RESEARCH**

Copyright 1996 by Wolfram Research, Inc. All rights reserved. Mathematica is a registered trademark of Wolfram Research, Inc. Experimental Data Analyst is a trademark of Wolfram Research, Inc. Mathematica is a registered trademark of Wolfram Research, Inc. Mathematica is also distributed under license from Wolfram Research, Inc.

Circle No. 33 on Readers' Service Card

MICROMANIPULATORS

PULLING POWER!

P-97

Pulling Power!

MICROELECTRODE BEVELLERS

-Microelectrodes -Patch pipettes

-Injection needles

The **P-97** gives you the power to

pull a variety of micropipettes,

accurately, reliably, and at

an affordable price!



SUTTER INSTRUMENT COMPANY

40 LEVERONI COURT, NOVATO, CA 94949

PHONE: 415.883.0128 FAX: 415.883.0572

INFO@SUTTER.COM

HTTP://WWW.SUTTER.COM

OPTICAL FILTERWHEELS





Circle No. 12 on Readers' Service Card